These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 26860026)

  • 21. Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease.
    Wens SC; Kroos MA; de Vries JM; Hoogeveen-Westerveld M; Wijgerde MG; van Doorn PA; van der Ploeg AT; Reuser AJ
    Mol Genet Metab; 2012 Nov; 107(3):485-9. PubMed ID: 23000108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
    Wang Z; Okamoto P; Keutzer J
    Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
    Kishnani PS; Beckemeyer AA; Mendelsohn NJ
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):1-7. PubMed ID: 22253049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute progression of neuromuscular findings in infantile Pompe disease.
    Burrow TA; Bailey LA; Kinnett DG; Hopkin RJ
    Pediatr Neurol; 2010 Jun; 42(6):455-8. PubMed ID: 20472203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pompe disease: design, methodology, and early findings from the Pompe Registry.
    Byrne BJ; Kishnani PS; Case LE; Merlini L; Müller-Felber W; Prasad S; van der Ploeg A
    Mol Genet Metab; 2011 May; 103(1):1-11. PubMed ID: 21439876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA.
    Xu F; Ding E; Migone F; Serra D; Schneider A; Chen YT; Amalfitano A
    J Gene Med; 2005 Feb; 7(2):171-8. PubMed ID: 15515143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infantile Pompe disease: clinical and genetic characteristics with an experience of enzyme replacement therapy.
    Cho A; Kim SJ; Lim BC; Hwang H; Park JD; Kim GB; Jin DK; Lee J; Ki CS; Kim KJ; Hwang YS; Chae JH
    J Child Neurol; 2012 Mar; 27(3):319-24. PubMed ID: 21940687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dissociated excitation-contraction coupling in infantile Pompe disease.
    Gutmann L; Jaynes M; Gyure K; Nance C; Gutmann L
    Muscle Nerve; 2017 Jul; 56(1):E4-E6. PubMed ID: 28120517
    [No Abstract]   [Full Text] [Related]  

  • 29. Enzyme replacement therapy for infantile-onset pompe disease: curse or cure?
    Willems J; Petros A; Brierley J
    Neurology; 2008 Jul; 71(5):380-1. PubMed ID: 18663187
    [No Abstract]   [Full Text] [Related]  

  • 30. Novel GAA sequence variant c.1211 A>G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease.
    Nilsson MI; Kroos MA; Reuser AJ; Hatcher E; Akhtar M; McCready ME; Tarnopolsky MA
    Gene; 2014 Mar; 537(1):41-5. PubMed ID: 24384324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late onset glycogen storage disease type II: pitfalls in the diagnosis.
    Papadimas GK; Spengos K; Papadopoulos C; Manta P
    Eur Neurol; 2012; 67(2):65-8. PubMed ID: 22179097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy.
    Katzin LW; Amato AA
    J Clin Neuromuscul Dis; 2008 Jun; 9(4):421-31. PubMed ID: 18525427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.
    Klinge L; Straub V; Neudorf U; Schaper J; Bosbach T; Görlinger K; Wallot M; Richards S; Voit T
    Neuromuscul Disord; 2005 Jan; 15(1):24-31. PubMed ID: 15639117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of antibodies in late-onset Pompe disease: a case series and literature review.
    Patel TT; Banugaria SG; Case LE; Wenninger S; Schoser B; Kishnani PS
    Mol Genet Metab; 2012 Jul; 106(3):301-9. PubMed ID: 22613277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gingival overgrowth in Pompe disease: a case report.
    de Gijt JP; van Capelle CI; Oosterhuis JW; van der Ploeg AT; van der Wal KG
    J Oral Maxillofac Surg; 2011 Aug; 69(8):2186-90. PubMed ID: 21783002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New insights into therapeutic options for Pompe disease.
    Richard E; Douillard-Guilloux G; Caillaud C
    IUBMB Life; 2011 Nov; 63(11):979-86. PubMed ID: 22002928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating.
    Kroos M; Pomponio RJ; van Vliet L; Palmer RE; Phipps M; Van der Helm R; Halley D; Reuser A;
    Hum Mutat; 2008 Jun; 29(6):E13-26. PubMed ID: 18425781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low anal sphincter tone in infantile-onset Pompe Disease: an emerging clinical issue in enzyme replacement therapy patients requiring special attention.
    Tan QK; Cheah SM; Dearmey SM; Kishnani PS
    Mol Genet Metab; 2013 Feb; 108(2):142-4. PubMed ID: 23266370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycogen storage disease type II (Pompe disease)--influence of enzyme replacement therapy in adults.
    Merk T; Wibmer T; Schumann C; Krüger S
    Eur J Neurol; 2009 Feb; 16(2):274-7. PubMed ID: 19138339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pompe disease : anesthesiological special features].
    Lehberger J; Roth R; Weingärtner K; Heesen M
    Anaesthesist; 2012 Mar; 61(3):229-33. PubMed ID: 22430553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.